Clinical trials: Advanced Tumor, open to volunteers
Urothelial Carcinoma, Biliary Tract Cancer
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
his single-center phase II clinical study enrolls patients with unresectable locally advanced or metastatic HER2-overexpressing biliary tract cancer or urothelial carcinoma who have failed standard treatment.
- Conditions
- Urothelial Carcinoma, Biliary Tract Cancer, HER2
- Trial name
- SHIELD (NCT07506057)
- Testing
- Trastuzumab+Serplulimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiujuan Qu
Gastric Cancer
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma that failed to be treated…
- Trial name
- NCT06417892
- Testing
- PD-1inhibitor, Fruquintinib, albumin paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of different doses of radiotherapy combined with sintilimab in locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06468644
- Testing
- chemoradiotherapy （CRT）+sintilimab 1, CRT+sintilimab 2
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Advanced Cancer
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
- Trial name
- NCT07269145
- Testing
- TQB3122 Capsules
- Where
- 5 sites in China
- Volunteers
- 86 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
IO Resistant Squamous and Nonsquamous NSCLC
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally.
- Trial name
- MarsLight-11 (NCT07217301)
- Testing
- TAK-928, Control Arm
- Where
- 50 sites in United States, China and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
HNSCC
Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
This single-center, open-label Phase II trial aims to evaluate the efficacy and safety of neoadjuvant combination therapy with Adebrelimab (anti-PD-L1), Dalpiciclib Isethionate (CDK4/6 inhibitor), and cisplatin chemotherapy in…
- Trial name
- NCT07778732
- Testing
- Adebrelimab Injection, Dalpiciclib Isethionate, Cisplatin
- Volunteers
- 32 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumors Cancer
First-In-Human Study of KHN922 for Injection
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
- Trial name
- NCT07514975
- Testing
- KHN922 for injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Digestive System Neoplasms
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 alone in subjects with advanced digestive system neoplasms.
- Trial name
- NCT06019702
- Testing
- iNeo-Vac-R01
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sir Run Run Shaw Hospital
Advanced (Unresectable or Metastatic) Melanoma
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced…
- Trial name
- NCT07221734
- Testing
- MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo®, US- sourced Opdivo®
- Where
- 86 sites in Bosnia and Herzegovina, Brazil and 11 more
- Volunteers
- 632 people
- Sponsor
- mAbxience Research S.L.
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
This study includes patients with advanced non-small cell lung cancer (NSCLC) - either unresectable stage III or stage IV adenocarcinoma without actionable driver mutations - who are treated with pembrolizumab in combination with…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation, NSCLC Adenocarcinoma
- Trial name
- NCT06951399
- Testing
- Pembrolizumab (KEYTRUDA®)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Melanoma
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene…
- Trial name
- NCT05983237
- Testing
- Fluzoparib Camrelizumab Temozolomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun Guo
Locally Advanced Rectal Carcinoma
Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer
The goal of this clinical trial is to investigate if the addition of modulated electro-hyperthermia (mEHT) improves tumor down-staging and pathological response in adult patients (20 years and above) with locally advanced rectal…
- Trial name
- mEHT (NCT07372300)
- Testing
- Hyperthermia
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Shih-Kai Hung
Metastatic Gastroesophageal Junction Adenocarcinoma
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Based on the current status and progress in the treatment of gastric cancer, our center prospectively designed a first-line comprehensive treatment plan for unresectable or postoperative recurrent advanced…
- Trial name
- NCT06329973
- Testing
- Fruquintinib in combination with Sintilimab and CAPEOX
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Cancer Hospital
Biliary Tract Cancer, Cholangiocarcinoma
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
This study is being done to see if the investigators can improve the outcome of patients with biliary tract cancer that do not qualify for surgery.
- Trial name
- NCT06546969
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Hodgkin Lymphoma
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy…
- Trial name
- Pembro-FLASH (NCT06045195)
- Testing
- Pembrolizumab
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Cologne
Cancer
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Study Objectives 1. Primary Objective: The core aim of this study is to investigate whether the sequential approach of Spatially Fractionated Radiotherapy followed by 3 cycles of induction chemotherapy combined with Iparomlimab…
- Trial name
- NCT07041788
- Testing
- Iparomlimab and Tuvonralimab Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Cancer, Malignancy
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient.
- Conditions
- Cancer, Malignancy, Refractory Cancer, Relapsed Cancer
- Trial name
- ANGELICA (NCT05302037)
- Testing
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Pancreatic Cancer
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
This study is an open-label, single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimab(AK112/SMT112) in combination with stereotactic body radiation therapy and chemotherapy in patients with pancreatic…
- Trial name
- NCT06491472
- Testing
- Ivonescimab, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease
Swedish Cardiac And Renal Failure Study-1
Previous studies have shown that patients with heart failure with reduced pumping function and preserved kidney function experience improved symptoms, longer survival, and fewer hospitalizations when treated with medications such…
- Trial name
- SCARF-1 (NCT07029503)
- Testing
- Eplerenone
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.